Literature DB >> 10394611

Quality of life in people with insomnia.

G K Zammit1, J Weiner, N Damato, G P Sillup, C A McMillan.   

Abstract

OBJECTIVE: To determine whether subjects with insomnia report greater reductions in quality of life (QoL) than subjects without insomnia when assessed with self-report instruments.
METHODS: Questionnaires were completed by individuals recruited through media advertisements and screened with a structured telephone interview. Data obtained from 261 individuals with insomnia (INS group) were compared with those of 101 individuals with no sleep complaint, or controls (CTL group).
RESULTS: Subjects in the INS group obtained lower mean sum scores on the Medical Outcomes Study Cognitive Scale than did subjects in the CTL group (25.34 +/- 0.34 vs 31.91 +/- 0.58, t = 9.53, p < 0.0001). The INS group also obtained lower mean scores on all subscales of the SF-36 Questionnaire compared with those in the CTL group (each, p < 0.0001 or lower), indicating impairments across multiple QoL domains. Psychiatric assessment revealed that subjects in the INS group obtained significantly higher mean item scores than subjects in the control group on the Zung Depression Scale (2.22 +/- 0.03 vs. 1.52 +/- 0.03, p < 0.0001) and the Zung Anxiety Scale (1.96 +/- 0.02 vs. 1.40 +/- 0.04, p < 0.0001). In addition, subjects in the INS group reported significantly greater impairments in specific QoL domains on the QoL inventory, and the Work and Daily Activities Inventory. No differences were observed between subjects in the INS group who were receiving treatment for insomnia versus those who were untreated.
CONCLUSIONS: The results of this study indicate that significant QoL impairments are associated with insomnia.

Entities:  

Mesh:

Year:  1999        PMID: 10394611

Source DB:  PubMed          Journal:  Sleep        ISSN: 0161-8105            Impact factor:   5.849


  85 in total

1.  A general model of the effects of sleep medications on the risk and cost of motor vehicle accidents and its application to France.

Authors:  J Menzin; K M Lang; P Levy; E Levy
Journal:  Pharmacoeconomics       Date:  2001-01       Impact factor: 4.981

2.  Treatment of insomnia in Parkinson's disease: a controlled trial of eszopiclone and placebo.

Authors:  Matthew Menza; Roseanne DeFronzo Dobkin; Humberto Marin; Michael Gara; Karina Bienfait; Allison Dicke; Cynthia L Comella; Charles Cantor; Lee Hyer
Journal:  Mov Disord       Date:  2010-08-15       Impact factor: 10.338

3.  A Novel Application of a Biopsychosocial Theory in the Understanding of Disturbed Sleep before and after Kidney Transplantation.

Authors:  Jacob M Williams; Christina S McCrae; James R Rodrigue; Pamela R Patton
Journal:  J Clin Sleep Med       Date:  2016-02       Impact factor: 4.062

4.  Neural correlates of working memory performance in primary insomnia.

Authors:  Sean P A Drummond; Matthew Walker; Erin Almklov; Manuel Campos; Dane E Anderson; Laura D Straus
Journal:  Sleep       Date:  2013-09-01       Impact factor: 5.849

5.  Psychometric evaluation of the Chinese version of the Pittsburgh Sleep Quality Index (CPSQI) in primary insomnia and control subjects.

Authors:  Pei-Shan Tsai; Shu-Yi Wang; Mei-Yeh Wang; Chein-Tien Su; Tsung-Tsair Yang; Chun-Jen Huang; Su-Chen Fang
Journal:  Qual Life Res       Date:  2005-10       Impact factor: 4.147

6.  Sleep in the Elderly: Burden, Diagnosis, and Treatment.

Authors:  W Vaughn McCall
Journal:  Prim Care Companion J Clin Psychiatry       Date:  2004

Review 7.  Management of insomnia in patients with chronic pain conditions.

Authors:  Frederic Stiefel; Daniele Stagno
Journal:  CNS Drugs       Date:  2004       Impact factor: 5.749

8.  Association of health-related quality of life with health examination including organic functions and lifestyles in Japanese employees.

Authors:  Tomoaki Kimura; Yoichi Ogushi; Masahiro Takahashi; Yukari Munakata; Satomi Ishii
Journal:  Qual Life Res       Date:  2004-03       Impact factor: 4.147

9.  Correlation between degree and quality of sleep disturbance and the level of neuropsychiatric impairment in patients with liver cirrhosis.

Authors:  Jayanta Samanta; Radha K Dhiman; Amit Khatri; Kiran K Thumburu; Sandeep Grover; Ajay Duseja; Yogesh Chawla
Journal:  Metab Brain Dis       Date:  2013-03-15       Impact factor: 3.584

10.  Zolpidem extended-release 12.5 mg associated with improvements in work performance in a 6-month randomized, placebo-controlled trial.

Authors:  Milton Erman; Alice Guiraud; Vijay N Joish; Debra Lerner
Journal:  Sleep       Date:  2008-10       Impact factor: 5.849

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.